🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🔥 #ASCO25 Re-challange with Trastuzumab Deruxtecan after grade 1 ILD is overall safe in a real-world population Some of these patients did not recover completely to grade 0 before re-challange Great presentation from Hope Rugo reassuring on ILD management in RWD

Impressive phase 2 data with the Trop2 ADC Sac-TMT for 1L mTNBC (n=41): ORR 70%, mPFS 13.4 months. High activity irrespective of PDL1 expression. Same setting of ASCENT-03/04. Confirms the feeling that, in the future, we’ll treat mTNBC with frontline Trop2 ADCs. #ASCO25

I think that's probably correct. In 2nd line, SC > chemo. By the additive property, we now see that SG + pembro > chemo + pembro. Control arm performed as in KN355 chemo/pembro. Seems like a good option, and supports growing idea that SG might be preferred in TNBC.

Presented at #ASCO25: A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results:

very interesting data from RCT that exercise reduces recurrence and improves OS in early colon cancer. We've waited a long time for data such as this nejm.org/doi/full/10.10…

The potential impact of this RCT is huge. First one to prove that exercise has benefits equal to many standard treatments for cancer. Wow! Congrats to #ChrisBooth, #KerryCourneya eg al. Go Canada! nejm.org/doi/full/10.10…

Such a well deserved standing ovation for Chris Booth and the Challenge trial. These data are quite powerful. Much stronger evidence than what we saw in plenaries today. #ASCO25

Are T-cells "morning people"?! Chronotherapeutic oncology always makes me marvel at the staggering number of variables to consider in the complex interplay between tumor, patient, & treatment (But for now I'm glad I frontload my clinic schedule with a.m. infusions!) #ASCO25

One more NEJM paper for the #BreastCancer community at #ASCO25: very important data with use of #elinzanetant to help patients struggling with vasomotor symptoms during endocrine therapy OncoAlert

With synchronous publication in NEJM, Fatima Cardoso ABC Global Alliance shows Elinzanetant reduces vasomotor symptoms (hot flashes) for patients on ET with HR+ BC #ASCO25

Faculty in the ASCO- ESMO - Eur. Oncology joint session on “Biomarker-driven Therapeutics: Translating Innovation into Practice” #asco25 FabriceAndre Robin Zon Arturo LoAIza-Bonilla, MD MSEd Benedict Westphalen Teresa Amaral

ASCO 2025. Proud to co-author a poster, networked with global experts and caught up with friends in the oncology community. See you again in ASCO 2026. #asco25 #asco26 Melvin LK CHUA | FRCR, PhD, FASCO Herbert Loong, MBBS, FASCO Kevin Chua Stephanie Saw Yuji Uehara, MD

Timely and much-needed recommendations from ASCO We hope academic medical centers implement them without delay—for the well-being of oncologists and the future of cancer care. ASCO Journal of Clinical Oncology OncoAlert Eric Winer, MD Clifford Hudis Julie Gralow Jame Abraham, MD, FACP Erika Hamilton, MD

Excited to share our new study on how resistance to AKT inhibition is linked to lineage differences within breast cancer 👇🏽biorxiv.org/content/10.110… and also surprisingly/worryingly good AI generated podcast 🎧notebooklm.google.com/notebook/28ebc…

Thanks to the whole ⁦Annals of Oncology⁩ team, ⁦FabriceAndre & all the authors for driving up the quality of the journal (IF64)⁩. We’re always on the lookout for new potentially practice changing ideas & are building a new leadership team to make things better ESMO - Eur. Oncology⁩

Happy to share our latest #review on #neoadjuvantimmunotherapy: an extensive overview of current and emerging data in NSCLC, TNBC, GI + bladder cancers, melanoma and many more: written with close friends and KOLs published today in Nature Cancer MarleenKokLab doi.org/10.1038/s43018…

Throwback Thursday... Reminding myself of the bevacizumab saga in advanced breast cancer. Bispecific VEGF/PDL-1 inhibitors are now being explored. What did we learn? Bevacizumab for Advanced Breast Cancer: All Tied Up With a RIBBON? | Journal of Clinical Oncology

Thank you for all the support 👏🏼🙏🏼Daniel Tan Rebecca Dent Ravindran Kanesvaran Gopal Iyer Ya Hwee Tan Evelyn Wong Shuting Han Special mention to Shiling and Daniel Ang!

🚨Just out in Clinical Cancer Research our analysis on the recurrence timing after neoadjuvant chemo-immunotherapy in early-stage TNBC We analyzed 5 major trials 👉 Early relapse: up to 83% of all recurrences🤯 1/ 🧵 Why this matters 👇 🔗 Full article: doi.org/10.1158/1078-0…

I would agree! Early detection and improved therapies including immunotherapy have made early stage TNBC curable for most. Still room to improve detection, treatments, and side effects of treatment!